Literature DB >> 16360420

Histological chorioamnionitis and neonatal leukemoid reaction in low-birth-weight infants.

Vincenzo Zanardo1, Stefania Vedovato, Daniele D Trevisanuto, Agnese Suppiej, Erich Cosmi, Gian Franco Fais, Silvia Chiarelli.   

Abstract

We investigated whether histological chorioamnionitis (HCA) is a risk factor predisposing to leukemoid reaction (LR) and whether LR is associated with the preterm parturition syndrome and the systemic fetal inflammation response syndrome. A prospective histological study on placentas was performed in preterm infants (<or=32(+6) weeks' gestation) admitted to level III neonatal intensive care unit of Padua University from January 1998 to December 2003. Development of LR was related to evidence of HCA. Among the placentas of the 223 preterm examined infants, 61 (27%) were diagnosed with HCA. Overall incidence of LR was 5.3%. Of 61 preterm neonates with HCA, 8 (13%) developed LR; moreover, 4 (2%) of 162 preterm infants without HCA developed LR (odds ratio = 7.4). Neonates with both LR and HCA differ from neonates with LR and without HCA in occurrence of prolonged rupture of membranes (62.5% versus 0%, P < .01), mode of delivery (37.5% versus 100% cesarean delivery, P < .01), gestational age (26 +/- 1.6 versus 29.7 +/- 1.7 gestational weeks, P < .01), and bronchopulmonary dysplasia incidence (63% versus 25%, P < .01). Histological chorioamnionitis placental findings increase the risk for neonatal LR. The LR in low-birth-weight neonates with HCA is significantly associated with earlier delivery and bronchopulmonary dysplasia. Pathogenetic mechanisms of neonatal LR in low-birth-weight infants without HCA remain undefined.

Entities:  

Mesh:

Year:  2005        PMID: 16360420     DOI: 10.1016/j.humpath.2005.09.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  1 in total

1.  Extreme hyperleucocytosis of the premature.

Authors:  Esther Jansen; Judith Emmen; Thilo Mohns; Albertine Donker
Journal:  BMJ Case Rep       Date:  2013-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.